Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal up3.760 +0.050 (+1.348%)

09/09/2021 11:33

Luye Pharma (02186) signs agreement with ESTEVE

[ET Net News Agency, 9 September 2021] Luye Pharma Group Ltd. (02186) said Luye Pharma
Switzerland AG (Luye Switzerland), a wholly owned subsidiary of the company, and ESTEVE
Pharmaceuticals S.A. (ESTEVE) have entered into an agreement under which ESTEVE is granted
the exclusive rights to commercialize the new drug, Rivastigmine Multi-Day Transdermal
Patch (Rivastigmine MD or LY30410), in Spain.
Rivastigmine MD is a twice-weekly innovative patch formulation for the treatment of mild
to moderate dementia associated with Alzheimer's disease. It was developed by the group on
its proprietary transdermal patch platform and is one of the group's core products in the
CNS therapeutic field. (RC)

Remark: Real time quote last updated: 17/01/2022 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2022 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.